Table 1 Demographic characteristics, clinical data, and BDNF levels in antipsychotics-naive first-episode (ANFE) patients with schizophrenia (SCZ) and healthy controls.

From: The association between BDNF levels and risperidone-induced weight gain is dependent on the BDNF Val66Met polymorphism in antipsychotic-naive first episode schizophrenia patients: a 12-week prospective study

Variable

ANFE patients (n = 225)

Healthy controls (n = 125)

p value

Gender(male/female)

124/101

77/48

0.26

Age (years)

27.9 ± 9.3

27.6 ± 7.0

0.90

Education (years)

9.3 ± 3.9

10.3 ± 3.1

0.01

Smoker (n, %)

64 (28.4)

44 (35.2)

0.23

Weight (kg)

59.4 ± 11.7

66.7 ± 13.9

<0.001

BMI (kg/m2)

21.4 ± 3.5

23.5 ± 4.1

0.001

Age of onset (years)

26.2 ± 9.2

  

BDNF(ng/ml)

9.5 ± 3.9

11.8 ± 2.5

<0.001

BDNF Val66Met

  

0.54

Met/Met

55

34

 

Val/Met

112

54

 

Val/Val

58

36

 
  1. BMI body mass index; PANSS the positive and negative syndrome scale; BDNF brain-derived neurotrophic factor.
Back to article page